Startups
Edit
https://ajibio-pharma.com/
Ajinomoto Bio-Pharma Services
TrustedLast activity: 05.10.2026
Active
We help to improve the health of humankind.
Ajinomoto Bio-Pharma Services is contract development a
Ajinomoto Bio-Pharma Services is contract development a
Overview
Location
United States, California, San Diego
Employees
1001-5000
Phone
+1 888-425-8432
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 30, 2026 | Piramal Pharma Limited Announces Results for Q1 FY27 | MUMBAI, India, July 30, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter ... |
| Apr 16, 2026 | Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing | Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization. Ajinomoto Bio-Pharma S... |
| Dec 21, 2021 | Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units | /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a le... |
| Dec 2, 2021 | Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units | /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, Dec. 1, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in ... |
| Sep 15, 2021 | Antibody-Drug Conjugate Therapeutic Window Enhancement, Upcoming Webinar Hosted by Xtalks | Overall, Aji Bio-Pharma’s site-specific conjugation technology coupled with a novel cleavable linker, reduces heterogeneity, thus simplifying manufacturing and characterization of the ADCs, and enhances biological properties by increasing t... |
| Apr 1, 2021 | Covid-19 manufacturing roundup: Catalent gets the FDA's go-ahead on J&J shot; AstraZeneca taps a new contractor | The FDA has authorized an Indiana CDMO to produce and ship millions of doses of J&J’s Covid-19 vaccine. Catalent Pharma tweeted the news and an accompanying video from its Bloomington facility last week. The manuf... |
| Mar 30, 2021 | Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing USA - English USA - English | |
| Jan 13, 2021 | Oligonucleotide Therapeutics: Bridging from Research to Commercial, Upcoming Webinar Hosted by Xtalks | This webinar will examine potential CMC gaps that can occur between research and commercial stages, helping to improve project design and management. TORONTO (PRWEB) January 13, 2021 A well-designed chemistry, manufacturing and control (CMC... |
| Oct 6, 2020 | First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services' AJIPHASE Technology Receives FDA Approval USA - English USA - English España - español Deutschland - Deutsch France - Français |
Show more
Reviews 0
FAQ about Ajinomoto Bio-Pharma Services
What has the press written about Ajinomoto Bio-Pharma Services?
Parsers VC has collected 12 articles mentioning Ajinomoto Bio-Pharma Services, among them “Piramal Pharma Limited Announces Results for Q1 FY27” (Jul 30, 2026) and “Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing” (Apr 16, 2026).
Is Ajinomoto Bio-Pharma Services still active?
Yes, Ajinomoto Bio-Pharma Services is active; its latest activity on Parsers VC dates from Oct 5, 2026.